Elis: Disclosure of trading in own shares occured from June 23 to June 27, 2025 Disclosure of trading in own shares occurred from June 23 to June 27, 2025 Saint-Cloud, June 30, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from June 23 to June 27, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily ...
Elis : Déclaration des transactions sur actions propres du 23 juin au 27 juin 2025 Déclaration des transactions sur actions propres réalisées du 23 juin au 27 juin 2025 Saint-Cloud, le 30 juin 2025 Conformément à la réglementation relative aux rachats d’actions, notamment le Règlement (UE) 2016/1052, Elis déclare ci-après les achats d’actions propres réalisés du 23 juin 2025 au 27 juin 2025 dans le cadre du programme de rachat autorisé par la 24ème résolution du l’assemblée générale des actionnaires du 22 mai 2025 et annoncé le 6 mars 2025 : Présentation agrégée : Nom del'émetteu...
OSE Immunotherapeutics provides an update on ongoing proceedings OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25th, 2025, 8:00 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, 2025, regarding the request to retract the June 10th, 2025 order by the President of the Nantes Commercial Court, who authorized the postponement of the annual shareholders’ meeting of OSE, the deliberation is expected to occur on Tuesday, July 1st, 2025. OSE Immunotherapeutics will keep the market and its sharehol...
OSE Immunotherapeutics met à jour l’information sur les procédures en cours OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 25 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience le mardi 24 juin 2025, relative à la demande de rétractation de l’ordonnance du 10 juin 2025 du Président du Tribunal de Commerce de Nantes ayant autorisé l’ajournement de l’Assemblée générale annuelle de la Société, le délibéré devrait être rendu le mardi 1er juillet 2025. OSE Immunotherapeutics tiendra l...
Elis: Disclosure of trading in own shares occured from June 16 to June 20, 2025 Disclosure of trading in own shares occurred from June 16 to June 20, 2025 Saint-Cloud, June 23, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from June 16 to June 20, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily ...
Elis : Déclaration des transactions sur actions propres du 16 juin au 20 juin 2025 Déclaration des transactions sur actions propres réalisées du 16 juin au 20 juin 2025 Saint-Cloud, le 23 juin 2025 Conformément à la réglementation relative aux rachats d’actions, notamment le Règlement (UE) 2016/1052, Elis déclare ci-après les achats d’actions propres réalisés du 16 juin 2025 au 20 juin 2025 dans le cadre du programme de rachat autorisé par la 24ème résolution du l’assemblée générale des actionnaires du 22 mai 2025 et annoncé le 6 mars 2025 : Présentation agrégée : Nom del'émetteu...
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules Nantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a “Questions and Answers” document for all its shareholders and informs the market of ongoing procedures, in line with its commitment to holding the annual General Meeting with transparency, serene debates, and compliance with mark...
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale dans la transparence, la sérénité des débats, et le respect des règles de marché OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale dans la transparence, la sérénité des débats, et le respect des règles de marché NANTES, France, 20 juin 2025, 19 heures 30 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publie un document « Questions-Réponses » à destination de l’ensemble de ses actionnaires et informe le marché des procédures en cours, conformément à son engagement à t...
Feedback of the companies present at the ODDO BHF Nextcap Forum Company Country Market cap. (m) Company Country Market cap. (m) Accsys Technologies € 124 Hoffmann Green € 62 Afyren € 72 Hornbach € 1 451 Altri € 1 058 IDI € 537 AMG € 550 Implenia CHF 973 AmRest PLN 3 544 Jacquet Metals € 494 Arcure € 29 Kloeckner & Co € 653 Arverne 194 Knaustabbert € 144 Austriacard Holdings € 188 Lna Santé € 270 Bastide € 218 Medincell € 398 Befesa € 1 116 Nacon € 63 CAF € 1 649 N...
Our 14th edition of the ODDO BHF Nextcap Forum took place on 11 June in Paris, and on 12 June virtually. 96 companies and 170 investors were present for more than 700 meetings organized. Overall, we noted a still cautious tone from companies, with limited visibility on a solid rebound in a persistently uncertain market environment (geopolitical situation, US politics, etc.), even if there are some signs of recovery and certain sectors remain very well positioned (leisure, energy, defence). At th...
In this report we present our view on the long-term growth prospects for offshore wind in Europe, implications of the energy transition and the role of TSOs, such as Elia Group. We also focus on supply chain beneficiaries in our Benelux coverage. An increasing number of long-term framework contracts should provide improved risk-rewards to the supply chain, in our view. Furthermore, we take a deep dive into growth drivers and long-term financing for Elia Group, beyond the company's current financ...
A director at Kaufman & Broad sold 15,000 shares at 33.700EUR and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.